Get the Stockscreener App
0.1927
43.32%
-0.1473
After Hours:
.22
0.0273
+14.17%
Gossamer Bio Inc stock is traded at $0.1927, with a volume of 56.89M.
It is down -43.32% in the last 24 hours and down -56.79% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
See More
Previous Close:
$0.34
Open:
$0.3
24h Volume:
56.89M
Relative Volume:
3.58
Market Cap:
$45.23M
Revenue:
$48.47M
Net Income/Loss:
$-170.37M
P/E Ratio:
-0.257
EPS:
-0.7499
Net Cash Flow:
$-171.35M
1W Performance:
-43.11%
1M Performance:
-56.79%
6M Performance:
-93.68%
1Y Performance:
-81.47%
1-Day Range:
$0.1626
$0.30
1-Week Range:
$0.1626
$0.3551
52-Week Range:
$0.1626
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.1927 | 79.80M | 48.47M | -170.37M | -171.35M | -0.7499 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-24-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-24-26 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, - GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGC - GlobeNewswire Inc.
Gossamer Bio (GOSS) Reports Mixed Results for PROSERA in Q1 2026 Earnings Call - GuruFocus
Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval - MSN
GOSS Reports $99.2 Million in Cash Reserves for Future Operations - GuruFocus
Gossamer Bio (GOSS) Launches Exchange Offer for Convertible Notes - GuruFocus
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who - GlobeNewswire
Gossamer Bio Q1 2026 Deep Dive: EPS Misses by 17.6%, Revenue Up 72% - AlphaStreet
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - GlobeNewswire
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - Bluefield Daily Telegraph
GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - TradingView
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS) - Yahoo Finance
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 - PharmiWeb.com
Gossamer Bio earnings missed by $0.03, revenue topped estimates - Investing.com Canada
Earnings call transcript: Gossamer Bio Q1 2026 shows revenue beat, EPS miss - Investing.com Canada
Gossamer Bio Releases Q1 2026 Financial Results - AlphaStreet
Gossamer Bio Q1 Earnings Call Highlights - MarketBeat
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Gossamer Bio Q1 2026 Earnings Call Transcript - MarketBeat
Gossamer Bio stock falls 5% on earnings miss despite revenue beat By Investing.com - Investing.com South Africa
Gossamer Bio stock falls 5% on earnings miss despite revenue beat - Investing.com India
Q1 2026 Gossamer Bio Inc Earnings Call Transcript - GuruFocus
GOSS: Seralutinib showed significant vascular benefits in PAH, with a major debt reduction plan underway - TradingView
GOSS Reports Strong Q1 Revenue and Advances Regulatory Efforts - GuruFocus
Gossamer Bio Restructures Debt and Advances Seralutinib Program - TipRanks
Gossamer Bio launches exchange offer for convertible notes - Investing.com
Gossamer Bio Enters Noteholder Support Pact to Advance Convertible Notes Exchange - TradingView
Gossamer Bio Q1 net loss widens on higher R&D expenses - TradingView
Gossamer Bio (GOSS) proposes $72M secured notes, 317.6M shares and 150M warrants in debt swap - Stock Titan
Gossamer Bio launches exchange offer and consent solicitation intended to eliminate over $120 million of debt with existing noteholder support - marketscreener.com
Debt exchange and FDA path shape Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support - Yahoo Finance
BRIEF-Gossamer Bio Q1 EPS USD -0.2 - TradingView
GOSS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Gossamer Bio Inc stock (US38198T1034): Q1 2026 earnings in focus after steep share price slide - AD HOC NEWS
Gossamer Bio, Inc.Common Stock (NQ: GOSS - FinancialContent
Gossamer Bio stock (US38198T1034): FDA decision and restructuring put focus on future pipeline - AD HOC NEWS
GOSS SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Gossamer - The National Law Review
GOSS Should I Buy - Intellectia AI
Gossamer Bio to Announce First Quarter 2026 Financial Results and - The National Law Review
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio: Q1 Earnings Snapshot - Barchart.com
Earnings Preview: Gossamer Bio to Report Financial Results Post-market on May 18 - Moomoo
Gossamer Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gossamer Bio, Inc. 1Q 2026: Revenue $16.96M, EPS ($0.2) — 10-Q Summary - TradingView
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Gossamer Bio (NASDAQ: GOSS) warns on going concern as Q1 loss widens - Stock Titan
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action - GlobeNewswire
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):